Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study - 22/09/20
Highlights |
• | Baricitinib, an anti-JAK1/JAK2, reduces cytokine release and SARS-Co-V2 entry. |
• | In a retrospective multicenter study baricitinib reduces COVID-19 mortality rate. |
• | Baricitinib reduces intensive care unit admissions of COVID-19 pneumonia. |
• | Baricitinb reduces SARS-CoV-2 viral burden detected by nasopharyngeal swab. |
• | Baricitinib used for 2 weeks was not associated with serious adverse events. |
Graphical abstract |
Keywords : COVID-19, Baricitinib, JAK1/2, Pneumonia, Retrospective study, SARS-Co-V2
Collaborators. Vieri Vannucchi MD, Division of Internal Medicine, Azienda USL Toscana Centro, S.Maria Nuova Hospital, Florence; Monica Todoerti, MD, Rheumatology Unit, AO SS. Antonio e Biagio e C. Arrigo, Alessandria; Massimiliano Parodi, MD, Rheumatology Unit, AO SS. Antonio e Biagio e C. Arrigo, Alessandria, Paola Rossi, MD, Rheumatology Unit, AO SS. Antonio e Biagio e C. Arrigo, Alessandria; Piero Davio, MD, Internal Medicine Department, AO SS. Antonio e Biagio e C. Arrigo, Alessandria; Pinuccia Omodeo, MD, Pulmonary Diseases Department, AO SS. Antonio e Biagio e C. Arrigo, Alessandria; Guido Chichino, MD, Infectious Diseases Department, AO SS. Antonio e Biagio e C. Arrigo, Alessandria, Ernesto Cristiano Lauritano, MD, Emergency Department, AO SS. Antonio e Biagio e C. Arrigo, Alessandria; Antonio Maconi, IRFI Infrastructure Research, Education, Innovation, AO SS. Antonio e Biagio e C. Arrigo – Alessandria; Anna Maria Di Carlo, Consultant, Division of Internal Medicine, Azienda Ospedaliera Ospedali RiunitiMarche Nord, Fano; Rita Girolimetti, Consultant, Division of Internal Medicine, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro; Chiara Pelosi, Consultant, Division of Internal Medicine, Hospital of Ariano Irpino, Avellino; Annamaria Bellizzi, Consultant, Division of Internal Medicine, Hospital of Ariano Irpino, Avellino; Luca Franco, Division of Internal Medicine, Hospital of Ariano Irpino, Avellino; Italy |
|
ClinicalTrials.gov Identifier: NCT04358614. |
Vol 81 - N° 4
P. 647-679 - octobre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.